Tags

Type your tag names separated by a space and hit enter

Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status.
Anal Biochem. 2022 Oct 15; 655:114750.AB

Abstract

Ovarian cancer (OV) is the second most mortal gynecological malignancy. The oncomarker CA125 has been used as the main ovarian cancer marker for diagnosing and screening ovarian cancer in stages I and II. Therefore, sensitive and real-time detection of CA 125 is critical in ovarian cancer monitoring. Various tests are used to diagnose the CA 125. In recent years, modern methods such as biosensor technology have replaced the old tests for rapid, sensitive and specific detection of CA 125. Various types of biosensors are being developed, among which Surface Plasmon resonance (SPR) biosensors are one of the most important and remarkable types. Considering the importance of SPR biosensors in the diagnosis of enocomarker CA 125, the main focus of the present study is to consolidate the research work from the past two decade to the present. Also, the advantages and challenges in SPR biosensors development have been considered in the detection of CA 125 oncomarker.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Valerievich Yumashev A
Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia.
Rudiansyah M
Division of Nephrology & Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat / Ulin Hospital, Banjarmasin, Indonesia.
Chupradit S
Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.
Kadhim MM
Department of Medical Laboratory Techniques, Dijlah University College, Baghdad, 10021, Iraq; Techniques Department, Al-Farahidi University, Baghdad, Iraq.
Turki Jalil A
Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq.
Abdelbasset WK
Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.
Suksatan W
Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, 10210, Thailand.
Mireya Romero Parra R
Department of General Studies, Universidad Continental, Lima, Peru.
Fakri Mustafa Y
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq.
Abdullaev B
Scientific Department, Akfa University, Tashkent, 111221, Uzbekistan.
Bidares R
Department of Anatomy, Histology Forensic Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: Ramtin.bds@gmail.com.

MeSH

Biosensing TechniquesEarly Detection of CancerFemaleHumansOvarian NeoplasmsSurface Plasmon Resonance

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35643149

Citation

Valerievich Yumashev, Alexei, et al. "Optical-based Biosensor for Detection of Oncomarker CA 125, Recent Progress and Current Status." Analytical Biochemistry, vol. 655, 2022, p. 114750.
Valerievich Yumashev A, Rudiansyah M, Chupradit S, et al. Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status. Anal Biochem. 2022;655:114750.
Valerievich Yumashev, A., Rudiansyah, M., Chupradit, S., Kadhim, M. M., Turki Jalil, A., Abdelbasset, W. K., Suksatan, W., Mireya Romero Parra, R., Fakri Mustafa, Y., Abdullaev, B., & Bidares, R. (2022). Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status. Analytical Biochemistry, 655, 114750. https://doi.org/10.1016/j.ab.2022.114750
Valerievich Yumashev A, et al. Optical-based Biosensor for Detection of Oncomarker CA 125, Recent Progress and Current Status. Anal Biochem. 2022 Oct 15;655:114750. PubMed PMID: 35643149.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optical-based biosensor for detection of oncomarker CA 125, recent progress and current status. AU - Valerievich Yumashev,Alexei, AU - Rudiansyah,Mohammad, AU - Chupradit,Supat, AU - Kadhim,Mustafa M, AU - Turki Jalil,Abduladheem, AU - Abdelbasset,Walid Kamal, AU - Suksatan,Wanich, AU - Mireya Romero Parra,Rosario, AU - Fakri Mustafa,Yasser, AU - Abdullaev,Bekhzod, AU - Bidares,Ramtin, Y1 - 2022/05/25/ PY - 2021/12/22/received PY - 2022/5/2/revised PY - 2022/5/20/accepted PY - 2022/6/2/pubmed PY - 2022/9/14/medline PY - 2022/6/1/entrez KW - Biosensors KW - CA 125 KW - Nanomaterial KW - Ovarian cancer (OV) KW - SPR SP - 114750 EP - 114750 JF - Analytical biochemistry JO - Anal Biochem VL - 655 N2 - Ovarian cancer (OV) is the second most mortal gynecological malignancy. The oncomarker CA125 has been used as the main ovarian cancer marker for diagnosing and screening ovarian cancer in stages I and II. Therefore, sensitive and real-time detection of CA 125 is critical in ovarian cancer monitoring. Various tests are used to diagnose the CA 125. In recent years, modern methods such as biosensor technology have replaced the old tests for rapid, sensitive and specific detection of CA 125. Various types of biosensors are being developed, among which Surface Plasmon resonance (SPR) biosensors are one of the most important and remarkable types. Considering the importance of SPR biosensors in the diagnosis of enocomarker CA 125, the main focus of the present study is to consolidate the research work from the past two decade to the present. Also, the advantages and challenges in SPR biosensors development have been considered in the detection of CA 125 oncomarker. SN - 1096-0309 UR - https://www.unboundmedicine.com/medline/citation/35643149/Optical_based_biosensor_for_detection_of_oncomarker_CA_125_recent_progress_and_current_status_ DB - PRIME DP - Unbound Medicine ER -